Reported 5 months ago
The article discusses three reasons to consider buying CRISPR Therapeutics stock. Firstly, the company's first commercialized product, Casgevy, is set to ramp up its global rollout, potentially increasing revenue. Secondly, the company's pipeline includes programs targeting large markets, such as cardiovascular diseases, with significant potential for growth. Lastly, CRISPR Therapeutics has a solid financial position with a substantial cash reserve and no long-term debt, providing flexibility for future investments.
Source: YAHOO